Our Mission
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe and effective technologies that can transform cancer care.
The Galleri test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.
Multi-cancer early detection (MCED) blood tests analyze DNA that has been shed by all cells, including cancer cells, into the bloodstream, looking for abnormal methylation patterns on those cell-free DNA fragments that may indicate the presence of cancer.
GRAIL’s methylation technology preferentially targets the most informative regions of the genome and uses machine-learning algorithms to detect methylation patterns associated with cancer and when found, to predict the cancer signal origin.
Who We Are
GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable.
;
Advances in next-generation sequencing and machine learning have enabled the development of multi-cancer early detection (#MCED) testing. Learn more: https://bit.ly/45wf8ux
Get GRAIL news sent straight to your inbox with our monthly newsletter. Sign up now to receive our upcoming issue: https://bit.ly/44j6Jt6
This week, @johnhancockusa, @Point32Health and GRAIL participated in a panel discussion at the @BostonGlobe Summit. These partners have led the way in their respective industries making multi-cancer early detection available to their customers and patients. #GlobeSummit
In the latest episode of our podcast #TheCancerSignal, @AICAF_Org CEO Melissa Buffalo delves into why Indigenous communities face disparities in cancer screening and care, and what can be done to address this.
🎙️Listen here: https://bit.ly/46eTqer
According to @AmericanCancer, cancer is the leading cause of death among Hispanic people – which makes proactive screening particularly important among this community. Hear Cindy’s story: https://bit.ly/44RHQVD #HispanicHeritageMonth
On September 20 at #GlobeSummit, representatives from @Point32Health, @johnhancockusa, and @GrailBio will discuss how they are working to increase access to a multi-cancer early detection screening test to help people live healthier lives. Register now: https://globesummit2023.splashthat.com/social